Member Info for Lottohopes

News: you shouldn't have to change your style or language, whilst posting. You are who you are. People have to just take that at face value. I have a lot to learn.....Good luck

Hi News...hope your well! Good to see you here

I do think the 6.4p broker target is rubbish if Novartis gets approval for CART. We will know in 3-6 months. Just my humble opinion

Lol master baker! What's your average? 12p? Go on make me feel better

I agree waiting game. Small percentage royalties. Novartis news first quarter next year, will change our cash flow.....just my two pence (actually my 6 pence as I got spiked)

RNS out

RNS out: retinostat study safety and tolerability established in 21 pt study. Now to prove it works!

Shatter: thanks for reply..

So another dilution. We knew the company was running out of cash third Q, so will this be perceived as good news/avoiding uncertainty or bad news?

Shatter: the other upside is Novartis CART related blood cancer treatments getting approval possibly early 2017: I reckon that can be very positive for this? Not a ramp just an observation.

Thanks Shatter. I m hoping some news stems the slide downwards we have been seeing....previous projection was for cash upto third quarter, so in the next 4-6 weeks we should have an update? A: more loans/dilution, B: some money coming from manufacturing/licensing to tide us over, is this reasonable assumption?

Anyone who works in this field, with any idea what this capacity expansion means commercially? No comment on existing revenue from manufacturing side?

I think OXB has acknowledged that Novartis is scaling up to eventually supply it's own material for the CART trials; at that point, royalties for IP only. If CART gets licenses for any of the conditions: and it looks very promising for the blood cancers atleast, Oxb is quids in.

Just looking for updates on CART, found this http://www.forbes.com/sites/arleneweintraub/2016/06/07/heres-whats-next-for-cancer-killing-t-cells-after-strong-asco-showings/#303ae6541d40 Also found an old article on CART in general which is interesting: apologies if it's been posted before, just thought something to distract us from the gloom of our paper losses :-) http://mobile.the-scientist.com/article/42462/the-car-t-cell-race And lastly CART with PENN and Novartis in GBM https://www.sciencedaily.com/releases/2016/04/160418095144.htm

Shatter: If the broker appointment is for a share issue or share consolidation, why has the SP reacted positively? My hope would be that this is leading to good news ie merger or further contracts etc....just a waiting game!

Anyone any ideas why this sp is in free fall?

I agree the directors could not buy if news was price sensitive. But surely these folks have a longer term view of how studies are progressing, unreported data etc?

Now we know why the directors have been topping up. Good news on the study side of things: 4 years plus and gene expression continues for both PD and wet AMD. And the second manufacturing site will hopefully show new revenues by third quarter. What's not to like?!! Patience will pay off for those that have waited decades. GLA

Thank you CH. That's very helpful. Wish I didn't have to choose!

I do think this is a massively overlooked share, possibly due to the market not knowing which box to put it in, or how to value it (as Woodford commented). My question:,if you had to choose between this one and Imperial Innovations, which one would you choose?